MT1M: A Protein Implicated in T Cell Development (G4499)

Target Name: MT1M

NCBI ID: G4499

MT1M

MT1M: A Protein Implicated in T Cell Development

MT1M, also known as Metallothionein 1Y, is a protein that is expressed in a variety of tissues throughout the body. It is a member of the thymus family, which includes proteins that play a critical role in the development and maintenance of the thymus gland.

The thymus gland is a vital organ that is responsible for the development and maturation of T cells, which are a crucial part of the immune system. T cells are responsible for recognizing and responding to foreign substances in the body, and they are an important part of the immune system.

MT1M is a protein that is expressed in the thymus gland, and it is believed to play a critical role in the development and maintenance of T cells. It is made up of four domains: an N-terminus, a C-terminus, a middle transmembrane region, and an optional C-terminal region.

The N-terminus of MT1M is a protein that is known as MTC1 (Metallothionein C1), and it is a key component of the thymus gland. MTC1 is a 21-kDa protein that is made up of 115 amino acids. It is located at the center of the thymus gland and is involved in the development and maintenance of T cells.

The C-terminus of MT1M is a protein that is known as MTC2 (Metallothionein C2), and it is also a key component of the thymus gland. MTC2 is a 19-kDa protein that is made up of 114 amino acids. It is located at the edge of the thymus gland and is involved in the development and maintenance of T cells.

The middle transmembrane region of MT1M is a region that is located between the N-terminus and the C-terminus. It is thought to play a critical role in the regulation of the movement of cells in the thymus gland.

The C-terminal region of MT1M is a region that is located at the end of the protein. It is not known to have any function in the thymus gland.

MT1M is a protein that is expressed in a variety of tissues throughout the body, including the thymus gland, the bone marrow, the spleen, and the lymph nodes. It is thought to play a critical role in the development and maintenance of T cells, which are a crucial part of the immune system.

Due to its involvement in the development and maintenance of T cells, MT1M is a potential drug target or biomarker. Researchers are currently working to develop methods for delivering MT1M directly to the thymus gland, with the goal of using it as a treatment for conditions such as thymus insufficiency and myelodysplastic syndromes.

In addition to its potential use as a drug, MT1M is also being studied as a biomarker for the diagnosis and prognosis of various diseases. For example, researchers have used MT1M as a marker for the diagnosis of acute myeloid leukemia, and they have found that higher levels of MT1M are associated with a more favorable prognosis.

Overall, MT1M is a protein that is expressed in the thymus gland and is involved in the development and maintenance of T cells. It is a potential drug target or biomarker, and researchers are currently working to develop methods for delivering MT1M directly to the thymus gland as a treatment for various diseases.

Protein Name: Metallothionein 1M

Functions: Metallothioneins have a high content of cysteine residues that bind various heavy metals; these proteins are transcriptionally regulated by both heavy metals and glucocorticoids

The "MT1M Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MT1M comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets